跳至主要内容
临床试验/CTRI/2015/01/005359
CTRI/2015/01/005359已完成3 期

A Multicentric, Prospective, Double blind, Randomized, Comparative Clinical trial to evaluate the Efficacy and Tolerability of Efonidipine in the treatment of Hypertension

Zuventus Healthcare Ltd12 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2015年1月30日最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
200
试验地点
12
主要终点
•Proportion of patients achieving JNC VII target BP of 140/90 mm Hg by the end of treatment

研究概览

简要总结

A Multicentric, Prospective, Double blind, Randomized,Comparative Clinical trial to evaluate the Efficacy and Tolerability of 

Efonidipinein the treatment of Hypertension

The aim of the study is to establishnon-inferiority of Efonidipine hydrochloride when compared with Amlodipine inthe management of hypertension

Primary Objective

  • To assess the efficacy of Efonidipine 40 mg given once a day orally in alleviating symptoms of hypertension

Secondary Objective

  • To evaluate the safety & tolerability of the investigational drug in Indian patients.
  • Toevaluate patient compliance

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Double Blind Double Dummy

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients aged 18 to 65 years 2.Patients with stage 1 hypertension as per Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VII) 3.Patients with heart rate > 83 beats/min 4.Patients ready to sign informed consent.

排除标准

  • 1.Patients with severe hypertension with sitting systolic BP ≥ 180 mm Hg 2.Patients with history of stroke or myocardial infarction in the previous 6 months 3.Patients with congestive heart failure, sick sinus syndrome or sinus bradycardia (< 50 beats/min) 4.Patients with second- or third-degree atrioventricular block 5.Patients with documented hypersensitivity to dihydropyridine CCBs 6.Patients with hepatic disease with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper normal limit 7.Patients with renal disease with a serum creatinine concentration > 2.0 mg/dL 8.Patients with uncontrolled diabetes, (hemoglobin A1C > 9%), renal artery stenosis, or secondary hypertension 9.Pregnant women or nursing mothers 10.Females with child bearing potential (considerations relate to choice of contraception, planning for pregnancy and overall obstetric care during pregnancy) 11.Patients with history of alcohol dependence, alcohol abuse or drug abuse 12.Patients with history of chronic smoking (more than 10 units per day of cigarettes, bidis, or any other form) 13.Patients scheduled for surgery anytime during the study 14.Patient receiving some other drug during the study besides that in the protocol that could possibly alter the bio availability of the drug 15.The patient previously been participated in any other clinical trial within the last month.

结局指标

主要结局

•Proportion of patients achieving JNC VII target BP of 140/90 mm Hg by the end of treatment

时间窗: 28 Days

•Proportion of patients achieving heart rate 83 beats per minute by the end of treatment (as per Framingham Heart Study)

时间窗: 28 Days

次要结局

  • •Proportion of patients achieving JNC VII target BP of 140/90 mm Hg after 2 weeks of therapy
  • •Proportion of patients achieving heart rate 83 beats per minute after 2 weeks of therapy
  • •Symptom relief: Defined as the absence of the clinical symptom of dyspnea and palpitations after 4 weeks of therapy
  • Adverse events observed during the treatment period(28 Days)

研究者

申办方类型
Pharmaceutical industry-Indian

研究点 (12)

Loading locations...

相似试验